Evidence-based·Updated November 19, 2026·How we grade evidence

Dulaglutide (Trulicity)

PeptidePeptide drug

Dulaglutide (Trulicity) is a once-weekly injectable GLP-1 drug for type 2 diabetes. In the REWIND trial of 9,901 adults followed for a median of 5.4 years, it lowered major cardiovascular events by about 12% compared with placebo, and higher doses lower HbA1c and weight a little more than 1.5 mg. It also improved blood sugar in children 10 and older. Nausea, diarrhea and vomiting are common, and the label carries a boxed warning about thyroid C-cell tumors seen in rats.

Taking Dulaglutide (Trulicity) with other supplements or medications?Check your whole list for interactions. Free, no account.

Prescription medication: not a dietary supplement

This is an FDA-approved (or investigational) drug, not a supplement. It requires a prescription and medical supervision. The information below summarizes clinical-trial evidence for education only. It is not a recommendation to obtain or use it without a doctor.

Quick decision guide

May help most

Adults and children 10 years and older with type 2 diabetes, and adults with type 2 diabetes plus established cardiovascular disease or multiple cardiovascular risk factors, whose prescriber recommends a weekly injection

Common dosing range

Set by your prescriber. Adults start at 0.75 mg once weekly; the dose may rise to 1.5 mg, then in 1.5 mg steps at least 4 weeks apart up to 4.5 mg once weekly. Children 10 and older: 0.75 mg weekly, up to 1.5 mg

When to expect effects

Steady blood levels within 2 to 4 weeks; HbA1c changes were measured at 26 to 36 weeks in trials

Watch out for

Boxed warning: thyroid C-cell tumors in rats; it must not be used with a personal or family history of medullary thyroid cancer or MEN 2. Stomach side effects are common. Other risks include pancreatitis, low blood sugar with insulin or sulfonylureas, kidney injury from dehydration, gallbladder disease and diabetic eye complications

What is it

Dulaglutide is a prescription GLP-1 receptor agonist injected under the skin once a week, sold as Trulicity single-dose pens by Eli Lilly. The Trulicity label approves it, alongside diet and exercise, to improve blood sugar control in adults and children 10 years and older with type 2 diabetes, and to lower the risk of major cardiovascular events (cardiovascular death, nonfatal heart attack or nonfatal stroke) in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. Its label covers type 2 diabetes only: it is not approved for type 1 diabetes or as a weight-loss medicine.

Is it worth it for you?

Use this as a quick fit check, not a diagnosis.

Worth considering if…

You have type 2 diabetes and your prescriber recommends a once-weekly GLP-1 injection alongside diet and exercise
You have type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, the group in which it lowered heart events
You can learn the pen injection technique and report stomach side effects to your prescriber

Probably skip if…

You have a personal or family history of medullary thyroid cancer, or you have MEN 2 (contraindicated)
You have had a serious allergic reaction to dulaglutide or its ingredients (contraindicated)
You have severe gastroparesis, where the label says it is not recommended
You have type 1 diabetes, or you want a medicine approved for weight loss, which Trulicity is not

Evidence at a glance

lowering major cardiovascular events in type 2 diabetes

Good Evidence
Effect
Modest; about 12% fewer major cardiovascular events
Best fit
Adults 50 and older with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Time
Measured over a median of 5.4 years

blood sugar control in adults with type 2 diabetes (higher doses)

Good Evidence
Effect
All doses lowered HbA1c by about 1.5 to 1.8 points; 4.5 mg added about 0.24 points over 1.5 mg
Best fit
Adults with type 2 diabetes on metformin who need more blood sugar lowering
Time
Measured at 36 weeks

blood sugar control in children and teens with type 2 diabetes

Good Evidence
Effect
About 1.2 to 1.5 points lower HbA1c than placebo
Best fit
Children and teens 10 years and older with type 2 diabetes
Time
Measured at 26 weeks

body mass index in children and teens with type 2 diabetes

Limited Evidence
Effect
No difference from placebo
Best fit
Children and teens 10 years and older with type 2 diabetes
Time
Measured at 26 weeks

Evidence for 4 uses

AI-assisted evidence assessment. Talk to your doctor before relying on any single supplement.

lowering major cardiovascular events in type 2 diabetes

Disease adjunct
Good Evidence

In the double-blind REWIND trial, 9,901 adults aged 50 or older with type 2 diabetes and either previous cardiovascular disease or cardiovascular risk factors (mean age 66, median HbA1c 7.2%) took dulaglutide 1.5 mg weekly or placebo. Over a median of 5.4 years, nonfatal heart attack, nonfatal stroke or cardiovascular death occurred in 12.0% on dulaglutide versus 13.4% on placebo (hazard ratio 0.88). Death from any cause did not differ significantly (10.8% vs 12.0%). Stomach and bowel side effects were reported by 47.4% versus 34.1%. The trial was funded by the manufacturer.

Effect size
Modest; about 12% fewer major cardiovascular events
Time to effect
Measured over a median of 5.4 years
Best fit
Adults 50 and older with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors
Less likely
People without diabetes, who were not studied

Bottom line: Weekly dulaglutide modestly lowered heart attacks, strokes and cardiovascular deaths in people with type 2 diabetes over about 5 years.

blood sugar control in adults with type 2 diabetes (higher doses)

Biomarker support
Good Evidence

In the AWARD-11 trial, 1,842 adults with type 2 diabetes not controlled on metformin (mean HbA1c 8.6%, mean BMI 34.2) took dulaglutide 1.5, 3.0 or 4.5 mg weekly for 52 weeks. At 36 weeks, HbA1c fell by 1.77 points on 4.5 mg versus 1.54 on 1.5 mg, and weight fell by 4.6 kg versus 3.0 kg. The 3.0 mg dose beat 1.5 mg on HbA1c only in one of the two planned analyses. Nausea occurred in 13.4%, 15.6% and 16.4%, and vomiting in 5.6%, 8.3% and 9.3%, on the three doses. There was no placebo group, so the trial compares the doses with each other, not with no treatment.

Effect size
All doses lowered HbA1c by about 1.5 to 1.8 points; 4.5 mg added about 0.24 points over 1.5 mg
Time to effect
Measured at 36 weeks
Best fit
Adults with type 2 diabetes on metformin who need more blood sugar lowering
Less likely
People who cannot tolerate more nausea or vomiting at higher doses

Bottom line: Dulaglutide lowered HbA1c by about 1.5 to 1.8 points, and stepping up to 4.5 mg gave a little more lowering and weight loss than 1.5 mg.

blood sugar control in children and teens with type 2 diabetes

Biomarker support
Good Evidence

In the double-blind AWARD-PEDS trial, 154 young people aged 10 to under 18 with type 2 diabetes and a BMI above the 85th percentile, treated with lifestyle changes alone or with metformin with or without basal insulin, took dulaglutide 0.75 mg, 1.5 mg or placebo weekly. At 26 weeks, HbA1c rose 0.6 points on placebo and fell 0.6 and 0.9 points on the two doses, and 51% on dulaglutide versus 14% on placebo reached an HbA1c below 7.0%. BMI did not change differently between groups. Stomach side effects were more common with dulaglutide.

Effect size
About 1.2 to 1.5 points lower HbA1c than placebo
Time to effect
Measured at 26 weeks
Best fit
Children and teens 10 years and older with type 2 diabetes
Less likely
Children under 10, in whom it has not been studied; anyone hoping for a BMI change, which was not seen

Bottom line: In children and teens with type 2 diabetes, weekly dulaglutide lowered HbA1c, while it rose on placebo.

body mass index in children and teens with type 2 diabetes

No benefit found
Limited Evidence

In the same 26-week AWARD-PEDS trial of 154 young people with type 2 diabetes, BMI was a secondary outcome, and there were no differences between the dulaglutide and placebo groups in the change in BMI.

Effect size
No difference from placebo
Time to effect
Measured at 26 weeks
Best fit
Children and teens 10 years and older with type 2 diabetes
Less likely
Not applicable

Bottom line: In children with type 2 diabetes, dulaglutide did not change BMI more than placebo over 26 weeks.

How it works

Dulaglutide is a lab-made protein in which two copies of a modified GLP-1 hormone are joined to part of an antibody, which makes it last much longer than natural GLP-1. It activates the GLP-1 receptor, which increases insulin release when blood sugar is high, lowers glucagon and slows stomach emptying. The slowing of the stomach is largest after the first dose and fades with later doses. Its half-life is about 5 days, so one injection a week keeps steady levels, which are reached within 2 to 4 weeks. The label says it is presumed to be broken down like other proteins, and it lists no interactions through liver enzymes. Its main interaction effects come from lowering blood sugar and from slowing the absorption of tablets taken by mouth.

How to take it

1. Typical dose
Your prescriber sets the dose. For adults the Trulicity label starts at 0.75 mg injected under the skin once weekly. After 4 weeks it may be increased to 1.5 mg, and if more blood sugar control is needed, in 1.5 mg steps after at least 4 weeks on each dose, to a maximum of 4.5 mg once weekly. For children 10 years and older, the start is 0.75 mg weekly, with a maximum of 1.5 mg weekly after at least 4 weeks.
2. Higher studied dose
The highest labeled adult dose is 4.5 mg once weekly. In the AWARD-11 trial, 4.5 mg lowered HbA1c by 1.77 points versus 1.54 with 1.5 mg at 36 weeks.
3. Timing
Once a week on the same day, at any time of day. The label says a missed dose can be given if at least 3 days (72 hours) remain before the next scheduled dose; if less than 3 days remain, skip it and take the next dose on the usual day. The weekly day can be changed if the last dose was at least 3 days earlier.
4. With food
With or without food.
5. Split dosing
Not split. One pen is one weekly dose. If you also use insulin, give them as separate injections and never mix them; the same body area is fine, but not right next to each other.
6. How long to try
Long term, as your prescriber decides.

What to track

Blood sugar, especially if you also take insulin or a sulfonylurea
Nausea, vomiting or diarrhea, and signs of dehydration such as dizziness or making little urine
Severe stomach pain that may spread to the back, with or without vomiting (possible pancreatitis: seek care)
Changes in vision, if you have diabetic eye disease
A lump in the neck, trouble swallowing, shortness of breath or lasting hoarseness
Telling every surgeon or anesthesia team that you take it before any procedure

Bottom line: One injection a week, on a schedule your prescriber sets; watch blood sugar if you also use insulin or a sulfonylurea.

Safety

Know the common side effects, key cautions, and who should avoid it.

Common side effects

Nausea (12.4% on 0.75 mg and 21.1% on 1.5 mg versus 5.3% on placebo), diarrhea and vomitingBelly pain and decreased appetiteIndigestion and tirednessConstipation, gas, bloating, reflux and burpingInjection-site reactions, reported more often in children than adults

Serious risks

  • Risk of thyroid C-cell tumors (boxed warning). Dulaglutide caused dose-related thyroid C-cell tumors in rats after lifetime exposure. It is unknown whether it causes them, including medullary thyroid cancer, in humans. It is contraindicated with a personal or family history of medullary thyroid cancer or with MEN 2. One case of medullary thyroid cancer occurred in a trial patient whose calcitonin was already about 8 times the upper limit of normal before treatment.

  • Acute pancreatitis, including fatal and nonfatal hemorrhagic or necrotizing pancreatitis, has been seen with GLP-1 drugs including Trulicity. The label says to stop it if pancreatitis is suspected.

  • Low blood sugar with insulin or sulfonylureas; severe stomach and bowel reactions; acute kidney injury after dehydration from vomiting or diarrhea; serious allergic reactions including anaphylaxis and angioedema.

  • Diabetic eye complications (in REWIND, 8.5% versus 6.2% on placebo among people who already had diabetic retinopathy), gallbladder disease such as gallstones and cholecystitis, and food remaining in the stomach during anesthesia or deep sedation, which can lead to pulmonary aspiration.

Who should avoid it

Pregnancy & breastfeeding

Pregnancy: the Trulicity label says the limited data in pregnant women are not enough to determine a drug-related risk of birth defects or miscarriage, that animal studies suggest possible risk to the fetus, and that it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It also notes that poorly controlled diabetes in pregnancy carries its own risks to mother and baby, so pregnancy plans belong in a talk with your doctor. Breastfeeding: there are no data on dulaglutide in human milk, on the breastfed infant or on milk production; the label says to weigh the benefits of breastfeeding against the mother's need for Trulicity and any possible effects on the child.

Interactions

Insulin and sulfonylureas (for example glipizide, glimepiride)High

Together they raise the risk of low blood sugar, including severe episodes. The label says a lower dose of the insulin or sulfonylurea may be considered when Trulicity is started. Your prescriber decides, and you should know the signs of low blood sugar.

Warfarin and other tablets with a narrow safety rangeModerate

Dulaglutide slows stomach emptying and can slow the absorption of tablets taken by mouth, most after the first dose. At 1.5 mg it did not change absorption of tested medicines to a clinically relevant degree, but experience at 3 mg and 4.5 mg is limited. The label says levels of narrow-range medicines such as warfarin should be monitored.

Choosing a product

What to look for on the label, and what to be skeptical of.

Look for…

Trulicity single-dose pens dispensed by a licensed pharmacy on your own prescription
The pen strength on your label (0.75, 1.5, 3 or 4.5 mg per 0.5 mL)
A clear, colorless solution; the label says not to use it if it has particles or color
A Medication Guide and Instructions for Use with each fill

Be skeptical of…

"Natural GLP-1" supplements presented as a replacement for dulaglutide
Claims that Trulicity is an approved weight-loss medicine
Advice to stop or skip doses on your own around surgery without asking your prescriber
Online sellers offering dulaglutide pens without a prescription

Frequently asked questions

Is Trulicity approved for weight loss?⌄

No. The Trulicity label approves it to improve blood sugar control in type 2 diabetes (adults and children 10 and older) and to lower the risk of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. People often lose some weight on it, for example 3.0 to 4.6 kg at 36 weeks in one trial, but weight loss is not an approved use.

Can I take my supplements with dulaglutide?⌄

Our interaction database has no supplement pairs for dulaglutide, and we found no studies testing supplements with it. Because it lowers blood sugar and slows stomach emptying, ask your doctor or pharmacist to review any supplement marketed for blood sugar and any medicine taken by mouth that needs exact levels.

What if I miss a weekly dose?⌄

The label says to inject the missed dose as soon as possible if at least 3 days (72 hours) remain until your next scheduled dose. If less than 3 days remain, skip it and take the next dose on your usual day. Do not change your plan without asking your prescriber.

Does dulaglutide protect the heart?⌄

In the REWIND trial of 9,901 adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors, dulaglutide 1.5 mg lowered heart attacks, strokes and cardiovascular deaths combined by about 12% over a median of 5.4 years compared with placebo. Death from any cause did not differ significantly. It was not tested in people without diabetes.

Can it be used with insulin?⌄

Yes, the label allows it, but the risk of low blood sugar goes up and your prescriber may lower the insulin dose. Inject them separately and never mix them in one syringe; the same body area is fine as long as the injections are not right next to each other.

References by claim

lowering major cardiovascular events in type 2 diabetes

Gerstein et al., 2019 · PubMed (2019) link

blood sugar control in adults with type 2 diabetes (higher doses)

Frias et al., 2021 · PMC (2021) link

blood sugar control in children and teens with type 2 diabetes

Arslanian et al., 2022 · PubMed (2022) link

Safety

Trulicity (dulaglutide) prescribing information · DailyMed (FDA label) link

Track Dulaglutide (Trulicity) with Pilora

Set up dose reminders, check interactions, and join the community in the Pilora app.

Evidence-based·Updated Nov 19, 2026·Evidence current as of Nov 19, 2026·How we grade evidence

Disclaimer: This page summarizes published clinical-trial data for educational purposes and is not medical advice or a recommendation to use this prescription medication. Dosing, eligibility, and monitoring must be decided by a licensed prescriber.